BR0107708A - Vetor de expressão e secreção para interferon alfa humano e processo para produzir interferon alfa humano empregando o mesmo - Google Patents

Vetor de expressão e secreção para interferon alfa humano e processo para produzir interferon alfa humano empregando o mesmo

Info

Publication number
BR0107708A
BR0107708A BR0107708-2A BR0107708A BR0107708A BR 0107708 A BR0107708 A BR 0107708A BR 0107708 A BR0107708 A BR 0107708A BR 0107708 A BR0107708 A BR 0107708A
Authority
BR
Brazil
Prior art keywords
human alpha
alpha interferon
expression
hifn
same
Prior art date
Application number
BR0107708-2A
Other languages
English (en)
Other versions
BRPI0107708A8 (pt
Inventor
Se-Chang Kwon
Sung-Youb Jung
Ki-Doo Choi
Cha-Soon Kim
Sung-Min Bae
Gwan-Sun Lee
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR0107708A publication Critical patent/BR0107708A/pt
Publication of BRPI0107708A8 publication Critical patent/BRPI0107708A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"VETOR DE EXPRESSãO E SECREçãO PARA INTERFERON ALFA HUMANO E PROCESSO PARA PRODUZIR INTERFERON ALFA HUMANO EMPREGANDO O MESMO". Descreve-se nesta invenção: um vetor de expressão para a produção secretória de interferon alfa humano (hIFN<244>), compreendendo um polinucleotídeo que codifica uma seq³ência sinalizadora de enterotoxina II termoestável modificada em E. coli e um polinucleotídeo que codifica hIFN<244> ligado à sua extremidade 3'; um microorganismo transformado com o vetor de expressão; e um processo para produzir interferon humano de modo secretório cultivando o microorganismo, sendo o dito processo capaz de secretar uma forma solúvel de hIFN<244> ativo, a qual não contém um resíduo adicional de metionina no seu terminal N, dentro do periplasma de uma célula de E. coli.
BRPI0107708A 2000-01-19 2001-01-19 Vetor de expressão e secreção para interferon alfa humano e processo para produzir interferon alfa humano empregando o mesmo BRPI0107708A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020000002434A KR100360594B1 (ko) 2000-01-19 2000-01-19 인간 인터페론 알파의 발현 분비벡터 및 이를 이용한인터페론 알파의 생산 방법
PCT/KR2001/000097 WO2001057217A1 (en) 2000-01-19 2001-01-19 Expression and secretion vector for human interferon alpha and process for producing human interferon alpha by employing same

Publications (2)

Publication Number Publication Date
BR0107708A true BR0107708A (pt) 2002-11-19
BRPI0107708A8 BRPI0107708A8 (pt) 2016-06-07

Family

ID=19639684

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0107708A BRPI0107708A8 (pt) 2000-01-19 2001-01-19 Vetor de expressão e secreção para interferon alfa humano e processo para produzir interferon alfa humano empregando o mesmo

Country Status (14)

Country Link
US (1) US7052867B2 (pt)
EP (1) EP1250439B1 (pt)
JP (1) JP3751883B2 (pt)
KR (1) KR100360594B1 (pt)
CN (1) CN100436581C (pt)
AT (1) ATE371027T1 (pt)
AU (1) AU762053B2 (pt)
BR (1) BRPI0107708A8 (pt)
CA (1) CA2397527C (pt)
DE (1) DE60130100T2 (pt)
ES (1) ES2290156T3 (pt)
NZ (1) NZ520076A (pt)
RU (1) RU2230116C2 (pt)
WO (1) WO2001057217A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656452B1 (en) * 2003-08-13 2007-02-14 Sandoz AG Expression vectors, transformed host cells and fermentation process for the production of recombinant polypeptides
WO2005017174A2 (en) * 2003-08-13 2005-02-24 Sandoz Ag Process for the purification of recombinant polypeptides
GB0319601D0 (en) * 2003-08-20 2003-09-24 Sandoz Ag Production process
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
US7736653B2 (en) 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier
TWI544930B (zh) * 2007-10-01 2016-08-11 藥華醫藥股份有限公司 Ｎ端修飾之干擾素－α
FR2964434B1 (fr) 2010-09-07 2012-08-24 Walden Associates Ltd S A Amortisseur a haut pouvoir dissipatif et pratiquement sans huile
CA2847837A1 (en) 2011-09-05 2013-03-14 Hanmi Science Co., Ltd. A pharmaceutical composition for treating cancer, comprising interferon alpha conjugate
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3586386T2 (de) 1984-10-05 1993-01-14 Genentech Inc Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung.
JPS63230089A (ja) 1987-03-18 1988-09-26 Takeda Chem Ind Ltd 分泌発現による蛋白質の製造法
EP0626448A3 (de) 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
US5470719A (en) 1994-03-18 1995-11-28 Meng; Shi-Yuan Modified OmpA signal sequence for enhanced secretion of polypeptides
KR100316347B1 (ko) * 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법

Also Published As

Publication number Publication date
WO2001057217A1 (en) 2001-08-09
ATE371027T1 (de) 2007-09-15
EP1250439B1 (en) 2007-08-22
CA2397527A1 (en) 2001-08-09
DE60130100D1 (de) 2007-10-04
AU2890901A (en) 2001-08-14
JP3751883B2 (ja) 2006-03-01
CN1418251A (zh) 2003-05-14
CA2397527C (en) 2010-10-19
NZ520076A (en) 2003-07-25
RU2230116C2 (ru) 2004-06-10
JP2003521925A (ja) 2003-07-22
WO2001057217A9 (en) 2002-12-27
US20040151695A1 (en) 2004-08-05
US7052867B2 (en) 2006-05-30
EP1250439A1 (en) 2002-10-23
EP1250439A4 (en) 2004-04-07
ES2290156T3 (es) 2008-02-16
DE60130100T2 (de) 2008-05-15
BRPI0107708A8 (pt) 2016-06-07
KR100360594B1 (ko) 2002-11-13
KR20010073658A (ko) 2001-08-01
CN100436581C (zh) 2008-11-26
AU762053B2 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
BR0107708A (pt) Vetor de expressão e secreção para interferon alfa humano e processo para produzir interferon alfa humano empregando o mesmo
BR0009392A (pt) Polipeptìdeo, sequência de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, métodos para produzir uma sequência de ácido nucleico mutante e para produzir um polipeptìdeo, mutante de um polipeptìdeo com atividade de alafa-amilase, e, uso do polipeptìdeo ou variante
ES2103366T3 (es) Hidrolizado proteico de guisante, metodo para su produccion y su utilizacion.
DE69634640D1 (de) Mutierte alpha-amylase enzyme mit erhöhter stabilität
HUP9801886A2 (hu) Eljárás megfelelően kapcsolódó cisztinhidakat tartalmazó inzulin-prekurzorok előállítására
KR850000525A (ko) 재조합 dna기법에 의한 인체 igf 및 egf제조
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
ATE116661T1 (de) Insulinverbindungen.
ATE214144T1 (de) Sonnennachführung
BR9913698A (pt) Peptìdeo sinalizador de enterotoxina ii de e. coli modificado e um microorganismo expressando uma proteìna de fusão do peptìdeo e uma proteìna heteróloga
BR0016867A (pt) Precursor de análogo de insulina, sequência de polinucleotìdeo, vetor de expressão, célula hospedeira, e, processos para fabricar um precursor de análogo de insulina e para fabricar um análogo de insulina
MX9700273A (es) Benzamidinas sustituidas, su preparacion y empleo como sustancias medicamentosas.
BRPI0012265B8 (pt) fator estimulante de colônia de granulócitos humano modificado e processo para produzir o mesmo
ES2102312A1 (es) Procedimiento para la cristalizacion del iopamidol.
BRPI0506694A (pt) análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação
IT1262463B (it) Procedimento e dispositivo per la fabbricazione di vetro piano con caratteristiche migliorate.
BR9506866A (pt) Composiçao biologicamente purificada composiçao para utilizaçao como um agente anti-inflamatório processo para o tratamento de mamíferos tendo tecido inflamado e processo para á produçao de ciclomarin-a
DE69032136D1 (de) Polypeptid mit der zelladhäsions-, zellausdehnungs- und zellbeweglichkeitsaktivität von typ-iv-kollagen
BR0314255A (pt) Método de preparação de uma queratinase, bacillus recombinante, cultura bacteriana, e, método de preparação de um bacillus recombinante
ES2051954T3 (es) 2-aminotiazoles substituidos.
DE60236067D1 (en) Polypeptid mit alpha-isomaltosylglucosaccharidsynthase-aktivität
RU2002122088A (ru) Вектор для экспресии и секреции человеческого интерферона альфа(hifnальфа), штамм escherichia coli для экспрессии и секреции hifnальфа (варианты) и способ продуцирования hifnальфа
BR9714828A (pt) Vetor de expressão para a produção de um polipeptìdeo na levedura, cepa de levedura, e, processos para a produção de um vetor de expressão, para a produção de uma cepa de levedura e para a produção de um polipeptìdeo em uma cepa de levedura
BR0107655A (pt) Polinucleotìdeo isolado, vetor de expressão recombinante, polipeptìdeo, célula, método para produzir o polipeptìdeo, e, composição farmacêutica
ATE51246T1 (de) Hitze-vulkanisierbare siloxanzusammensetzungen mit verbesserter extrudierbarkeit.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: HANMI HOLDINGS CO., LTD. (KR)

Free format text: TRANSFERIDO DE: HANMI PHARM. CO., LTD.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: ANULACAO DO DESPACHO DE ARQUIVAMENTO PUBLICADO NA RPI NO 2176 DE 18/09/2012 POR TER SIDO INDEVIDO

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 15/63

Ipc: C12N 15/63 (2006.01), A61K 38/19 (2006.01), A61P 3

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B25G Requested change of headquarter approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements